Topics

Charles River to acquire Citoxlab, M&A ‘a top priority’

09:47 EST 14 Feb 2019 | Outsourcing-Pharma

Charles River is set to acquire Citoxlab for â448m ($510m) in cash, a deal which would bolster the CROâs safety assessment portfolio to support its long-term organic growth aspirations, says CEO.

Original Article: Charles River to acquire Citoxlab, M&A ‘a top priority’

NEXT ARTICLE

More From BioPortfolio on "Charles River to acquire Citoxlab, M&A ‘a top priority’"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...